Article Sidebar

PDF
Date Published: 17/02/2023
Abstract Views: 157
Views PDF: 96
DOI: https://doi.org/10.51298/vmj.v520i2.4168
Issue
Vol. 520 No. 2 (2022)
Section
Các bài báo
How to Cite
Trương, T. A., & Vũ, H. T. (2023). RESULT OF ADJUVANT CHEMOTHERAPY FOR STAGE III COLON CANCER IN OLDER PATIENT. Vietnam Medical Journal, 520(2). https://doi.org/10.51298/vmj.v520i2.4168

RESULT OF ADJUVANT CHEMOTHERAPY FOR STAGE III COLON CANCER IN OLDER PATIENT

Tuấn Anh Trương1,, Hồng Thăng Vũ1,2
1 Hanoi medical university
2 National Cancer Hospital

Main Article Content

Abstract

Aims: To identify the clinical characteristics, the laboratory characteristics, the result of adjuvant chemotherapy in older patient. Patients and methods: A retrospective combined prospective study. The patient older than age 65, diagnosed with resected stage III colon cancer  at Vietnam National Cancer Hospital, from January 2017 to June 2022, received XELOX or Capecitabine, recorded clinical characteristics, laboratory characteristics, treatment methods and overall survival. Results: 68 patients assigned to 2 group XELOX (n=56) and Capecitabine (n=12). The medium age at diagnosis was 69,9. Sex ratio: 1/1. The main presenting symptom was abdominal pain (73,5%), hemorrhagia (52,9%). ECOG 0 accounted for 80,9%. Common locations of tumor were sigmoid colon (52,9%) and right colon (23,5%). Major histological grade was  grade 2. Stage IIIA, IIIB, and IIIC were  4,4%, 89,7% and 5,9%. 3 – year OS and PFS were 75,1% and 80,2%. In XELOX group, 3 – year OS 3 and PFS were 78,7% and 73,1% vs 80,2% and 75,0% in Capecitabine group. There is no difference in OS and DFS between two groups. Conclusion: Either XELOX or capecitabine regimen improved DFS and OS in adjuvant therapy for stage III colon cancer in older patient. But benefit of oxaliplatin was unclear.

Article Details

Keywords

Stage III colon cancer in older patient

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 2021;71(3):209-249.
2. Sargent D, Sobrero A, Grothey A, et al. Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. JCO. 2009;27(6):872-877.
3. Schmoll HJ, Tabernero J, Maroun J, et al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. JCO. 2015;33(32):3733-3740.
4. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N Engl J Med. 2004;350(23):2343-2351.
5. McCleary NJ, Dotan E, Browner I. Refining the Chemotherapy Approach for Older Patients With Colon Cancer. JCO. 2014;32(24):2570-2580.
6. Nguyễn Thị Thu Hường (2011), Đánh giá đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị phẫu thuật kết hợp với hóa chất ung thư đại tràng di căn hạch tại bệnh viện K. Trường đại học Y Hà Nội, Hà Nội.
7. Nguyễn Quang Thái (2002), Nghiên cứu một số phương pháp chẩn đoán và kết quả sau 5 năm điều trị phẫu thuật ung thư đại tràng, Trường đại học Y Hà Nội, Hà Nội.
8. Võ Văn Kha (2017), Đánh giá kết quả hóa trị bổ trợ phác đồ XELOX trong ung thư biểu mô tuyến đại tràng giai đoạn II, III. Trường đại học Y Hà Nội, Hà Nội.
9. Đỗ Thị Thanh Mai (2017), Đánh giá kết quả điều trị ung thư đại tràng giai đoạn iii sau phẫu thuật triệt căn và hóa chất bổ trợ phác đồ XELOX. Trường đại học Y Hà Nội, Hà Nội.